uniQure Faces Class Action Lawsuit Over Alleged FDA Approval Misrepresentations

Rosen Law Firm has announced a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of shareholders. The lawsuit targets investors who purchased ordinary shares between September 24, 2025, and October 31, 2025. It alleges that uniQure misrepresented its business operations, specifically concerning FDA approval for its Pivotal Study design. Furthermore, the suit claims the company failed to disclose the need for additional studies, which impacted its Biologics License Application (BLA) timeline. Shareholders who incurred significant losses are urged to contact the firm by April 13, 2026, to understand their rights. This legal action introduces significant uncertainty and potential financial penalties for uniQure, casting a bearish outlook on its stock.